Piper Sandler Raises Henry Schein (NASDAQ:HSIC) Price Target to $95.00

Henry Schein (NASDAQ:HSIC) had its target price upped by equities researchers at Piper Sandler from $91.00 to $95.00 in a report released on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Piper Sandler’s price target would indicate a potential upside of 10.67% from the stock’s previous close.

Other analysts have also issued reports about the stock. Mizuho reduced their price objective on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Wall Street Zen cut shares of Henry Schein from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Robert W. Baird set a $97.00 target price on Henry Schein in a research report on Wednesday, May 6th. Citigroup initiated coverage on Henry Schein in a research note on Wednesday, April 15th. They set a “buy” rating and a $100.00 price target on the stock. Finally, UBS Group reaffirmed a “neutral” rating and issued a $89.00 price objective (up from $85.00) on shares of Henry Schein in a research note on Tuesday. Eight analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Henry Schein currently has an average rating of “Hold” and an average price target of $89.36.

Henry Schein Price Performance

Shares of Henry Schein stock traded up $0.13 during mid-day trading on Wednesday, reaching $85.84. 569,619 shares of the stock traded hands, compared to its average volume of 1,381,565. Henry Schein has a fifty-two week low of $61.94 and a fifty-two week high of $89.34. The stock has a market capitalization of $9.78 billion, a PE ratio of 25.97, a PEG ratio of 1.63 and a beta of 0.81. The business has a 50-day moving average of $81.47 and a 200 day moving average of $78.13. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 0.59.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.20 by $0.12. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The firm had revenue of $3.37 billion during the quarter, compared to analysts’ expectations of $3.34 billion. During the same quarter last year, the firm earned $1.15 earnings per share. The business’s revenue for the quarter was up 6.3% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, analysts predict that Henry Schein will post 5.32 EPS for the current year.

Insider Transactions at Henry Schein

In other Henry Schein news, Director William K. Daniel purchased 10,000 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was bought at an average price of $69.19 per share, with a total value of $691,900.00. Following the transaction, the director directly owned 20,000 shares of the company’s stock, valued at approximately $1,383,800. This represents a 100.00% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.89% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Invesco Ltd. increased its holdings in Henry Schein by 4.1% during the 3rd quarter. Invesco Ltd. now owns 4,731,698 shares of the company’s stock worth $314,043,000 after purchasing an additional 184,763 shares during the period. Southpoint Capital Advisors LP grew its position in shares of Henry Schein by 28.0% during the first quarter. Southpoint Capital Advisors LP now owns 3,200,000 shares of the company’s stock worth $235,840,000 after buying an additional 700,000 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Henry Schein by 2.0% in the first quarter. Dimensional Fund Advisors LP now owns 2,873,004 shares of the company’s stock worth $211,734,000 after acquiring an additional 56,687 shares during the last quarter. Ameriprise Financial Inc. increased its position in shares of Henry Schein by 11.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 2,523,014 shares of the company’s stock valued at $167,453,000 after purchasing an additional 256,156 shares during the last quarter. Finally, Bank of Montreal Can raised its holdings in shares of Henry Schein by 3,655.7% in the 4th quarter. Bank of Montreal Can now owns 2,144,773 shares of the company’s stock valued at $162,102,000 after purchasing an additional 2,087,666 shares in the last quarter. 96.62% of the stock is owned by institutional investors and hedge funds.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.